Skye Bioscience, Inc. acquired Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody Acquisition of Bird Rock Bio builds Skye’s position as

Skye Bioscience, Inc. -> Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody Acquisition of Bird Rock Bio builds Skye’s position as · $12 million

(OTCQB: SKYE) (“Skye” or the “Company”) announced that it has undertaken a strategic initiative that expands the Company’s resources and technologies focused on developing therapeutic products focused on the endocannabinoid system (“ECS”).